You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it.
NO
YES

HIGHLIGHTS

EVENTS

Leading medical-scientific event on Hemophilia held in Trieste, Italy

Kedrion-organized congress put replacement therapy, personalization and access to care in the spotlight

read more 

EVENTS

Kedrion scientific symposium at the 2019 PNS Conference in Genoa, Italy

A chance for world Key Opinion Leaders to debate possible new therapies for the treatment of CIPN

read more 

PLASMA & BIOTHERAPIES

First patient enrolled and treated in Kedrion’s CARES10 clinical study

Phase 3 study to assess efficacy, safety and pharmacokinetics of a 10% IVIg in the treatment of adult PID patients

read more 
  1. CORPORATE - 17-06-2016

    Kedrion Biopharma consolidates presence on Russian market

    Joint venture with Nacimbio of RosTECH group for a technology transfer to Kirov plant

    read more 
  2. CORPORATE - 26-05-2016

    SIPPET study results published in the “New England Journal of Medicine”

    This investigator-initiated clinical study involved 42 hemophilia treatment centers from all over the world

    read more 
  3. CORPORATE - 06-05-2016

    Kedrion Biopharma for Mother's Day

    We are committed to helping eliminate Rh disease worldwide by supporting initiatives like CURhE

    read more 
  4. EVENTS - 17-04-2016

    Kedrion initiatives for World Hemophilia Day 2016

    The goal is to improve access to treatments for people suffering from hemorrhagic conditions

    read more 

Pages

For more information please contact: pressoffice@kedrion.com